Potassium-specific effects of levosimendan on heart mitochondria.
In this study, we evaluated levosimendan, a new drug developed for the treatment of acute and decompensated heart failure, as a potential activator of ATP-sensitive potassium flux to the matrix of cardiac mitochondria. We estimated the KATP channel openers-induced increase in mitochondrial inner membrane permeability for potassium by registering changes in membrane potential of heart mitochondria, oxidizing endogenous substrates. We compared the effect of levosimendan with the effects of the known KATP channel openers diazoxide and pinacidil. Levosimendan (1 microM) accelerated potassium-specific DeltaPsi decrease by 0.15%/s, whereas 50 microM diazoxide by 0.10%/s, and 50 microM pinacidil by 0.08%/s, respectively. These results were confirmed by swelling experiments of non-respiring mitochondria in potassium nitrate medium. We found that levosimendan with an EC50 of 0.83 +/- 0.24 microM activates potassium flux to the mitochondrial matrix. This effect is discussed as a possible explanation of the anti-ischemic action of levosimendan.
Institute for Biomedical Research, Kaunas University of Medicine, Kaunas, Lithuania.
Dalia M
DM
Kopustinskiene
Piero
P
Pollesello
Nils-Erik L
NE
Saris
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D006835:Hydrazones / Q000494:pharmacology*; D008297:Male; D008565:Membrane Proteins / Q000187:drug effects / Q000378:metabolism*; D008929:Mitochondria, Heart / Q000187:drug effects* / Q000502:physiology; D011188:Potassium / Q000378:metabolism*; D015221:Potassium Channels; D011724:Pyridazines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D000077464:Simendan
D000889:Anti-Arrhythmia Agents; D006835:Hydrazones; D008565:Membrane Proteins; D015221:Potassium Channels; D011724:Pyridazines; C117780:mitochondrial K(ATP) channel; D000077464:Simendan; D011188:Potassium